Clinical Trial Update: Identification of Innovative Biomarkers to Predict Outcomes in Hepatocellular Carcinoma Treated With Tremelimumab and Durvalumab [NA]

View source ↗

Summary

This clinical trial update reports ongoing research to identify biomarkers that predict outcomes for hepatocellular carcinoma patients treated with tremelimumab…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Centre Hospitalier Universitaire de Besancon | Conditions: Hepatocellular Carcinoma | NA | Status: RECRUITING